Abstract
Harnessing RNA-based therapeutics for cancer, inflammation, and viral diseases is hindered by poor delivery of therapeutic RNA molecules. Targeting leukocytes to treat these conditions holds great promise, as they are key participants in their initiation, drug response, and treatment. The various extra- and intra-cellular obstacles that impediment the clinical implementation of therapeutic RNA can be overcome by utilizing drug delivery systems. However, delivery of therapeutic RNA to leukocytes poses an even greater challenge as these cells are difficult to reach and transfect upon systemic administration. This review briefly describes the existing successful delivery strategies that efficiently target leukocytes in vivo and discuss their potential clinical applicability.
| Original language | English |
|---|---|
| Pages (from-to) | 362-371 |
| Number of pages | 10 |
| Journal | Journal of Controlled Release |
| Volume | 342 |
| DOIs | |
| State | Published - Feb 2022 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Drug delivery
- Leukocytes
- Nanocarriers
- RNA
- mRNA
All Science Journal Classification (ASJC) codes
- Pharmaceutical Science
Fingerprint
Dive into the research topics of 'Delivery strategies of RNA therapeutics to leukocytes'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver